Unlock instant, AI-driven research and patent intelligence for your innovation.
Triazolo[4,5-d] pyrimidine derivatives and their application as purinergic receptor antagonists
What is Al technical title?
Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
A purine and receptor technology, applied in the field of adenosine A2A receptors and blocking adenosine receptors, which can solve problems such as no side effects
Inactive Publication Date: 2008-07-09
VERNALIS RES
View PDF2 Cites 1 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
Therefore, option A 2A Receptor antagonists could provide effective treatment for ADHD, but without the unwanted side effects of current treatments
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
Smart Image
Examples
Experimental program
Comparison scheme
Effect test
Embodiment
[0172] Synthesis Example
[0173] The following examples shown in Table 1 can be used to illustrate the present invention.
[0174] Table 1
[0175]
[0176]
[0177]
[0178]
[0179]
[0180]
[0181]
[0182]
[0183]
[0184]
[0185]
[0186]
[0187]
[0188]
[0189]
[0190]
[0191]
[0192]
[0193]
[0194]
[0195]
[0196]
[0197]
[0198]
[0199]
[0200]
[0201]
[0202]
[0203]
[0204]
[0205]
[0206]
[0207]
[0208]
[0209]
[0210]
[0211]
[0212]
[0213] The general synthetic methods used to prepare these examples are listed below as methods A-BH. Table 2 lists the methods and analysis data used in each example.
[0214] The following conditions were used for HPLC: Column: Waters Xterra RP 18 (50×4.6mm); particle size 5μM; mobile phase: MeOH: 10mM NH 4 OAc aqueous solution (pH 7 buffer); gradient: 50:50 isocratic elution for 1 minute, then a linear gradient from 50:50 to 80:...
Embodiment 211
[0469] A solution of 7-(2-furyl)-1H-[1,2,3]triazolo[4,5-d]pyrimidin-5-amine (101mg, 0.5mmol) in DMF (2mL) was used with 2 -Bromoacetophenone (100 mg, 0.5 mmol) and triethylamine (105 μL, 0.75 mmol), stirred at room temperature for 3 days, diluted with water (100 mL) and filtered. Purify the resulting solid by chromatography [SiO 2 ;Hexane:EtOAc, (3:1-1:1)], the title compound (20mg, 13%) was obtained as a yellow solid.
[0472] Add 6-(5-amino-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-ylmethyl)pyridine-2-carbaldehyde ( A solution of 62 mg, 0.193 mmol) in MeOH (20 mL) was treated with acetic acid (5 mL), dimethylamine (2-M in MeOH, 1.93 mL, 3.86 mmol) and sodium cyanoborohydride (242 mg, 3.86 mmol), Stir for 16 hours and concentrate in vacuo. The residue was treated with saturated sodium bicarbonate solution (20 mL), extracted with...
Embodiment 220
[0475] The 3-(6-bromomethyl-2-pyridylmethyl)-7-(2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-5- A solution of amine (200mg, 0.517mmol) and sodium cyanide (51mg, 1.03mmol) in DMF (5mL) was stirred at 60°C for 16 hours, poured into water (40mL), extracted with EtOAc (3×8mL), and The combined organic phase is dried (MgSO 4 ), concentrated in vacuo and purified by chromatography [SiO 2 ; Isohexane: EtOAc (1:1)] to obtain the title compound (50 mg, 26%) as a yellow solid.
[0476] Method AW
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
PUM
Login to View More
Abstract
The use of a compound of formula (I): wherein R1 is selected from H, alkyl, aryl, alkoxy, aryloxy, alkylthio, arylthio, halogen, CN, NR5R6, NR4COR5, NR4CONR5R6, NR4CO2R7 and NR4SO2R7; R2 is selected from aryl attached via an unsaturated carbon; R3 is selected from H, alkyl, COR5, CO2R7, CONR5R6, CONR4NR5R6 and SO2R7; R4, R5 and R6 are independently selected from H, alkyl and aryl or where R5 and R6 are in an NR5R6 group, R5 and R6 may be linked to form a heterocyclic group, or where R4, R5 and R6 are in a (CONR4NR5R6) group, R4 and R5 may be linked to form a heterocyclic group; and R7 is selected from alkyl and aryl, or a pharmaceutically acceptable salt thereof or prodrug thereof, in the treatment or prevention of a disorder in which the blocking of purine receptors, particularly adenosine receptors and more particularly A2A receptors, may be beneficial, particularly wherein said disorder is a movement disorder such as Parkinson's disease or said disorder is depression, cognitive or memory impairment, acute or chronic pain, ADHD or narcolepsy, or for neuroprotection in a subject; compounds of formula (I) for use in therapy; and novel compounds of formula (I) per se.
Description
[0001] This application is a divisional application of the patent application with the filing date of January 10, 2002 and the application number of 02806303.1. Technical field [0002] The present invention relates to triazolo[4,5-d]pyrimidine derivatives and their application in therapy. In particular, the present invention relates to the treatment of diseases in which reduced purinergic neurotransmission can be beneficial. The present invention particularly relates to blocking adenosine receptors, especially adenosine A 2A Receptors, and treatment of sports disorders such as Parkinson's disease. Background technique [0003] Movement disorders are serious health problems, especially among the elderly. These movement disorders are often the result of brain damage. Disorders involving the basal ganglia that cause movement disorders include Parkinson's disease, Huntington's disease, and Wilson's disease. In addition, movement disorders often appear as a sequelae of cerebral ischem...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
![Triazolo[4,5-d] pyrimidine derivatives and their application as purinergic receptor antagonists](https://images-eureka.patsnap.com/patent_img/6181a5ac-7c03-4c65-afe0-2ecd062c9e5b/s2008100024015c00011.PNG)
![Triazolo[4,5-d] pyrimidine derivatives and their application as purinergic receptor antagonists](https://images-eureka.patsnap.com/patent_img/6181a5ac-7c03-4c65-afe0-2ecd062c9e5b/s2008100024015d00061.PNG)
![Triazolo[4,5-d] pyrimidine derivatives and their application as purinergic receptor antagonists](https://images-eureka.patsnap.com/patent_img/6181a5ac-7c03-4c65-afe0-2ecd062c9e5b/s2008100024015d00171.PNG)
Login to View More 
Login to View More